

**THE INTERNATIONAL SYMPOSIUM ON
EBV & KSHV, RELATED AGENTS &
DISEASES - 3RD JOINT MEETING**

JUNE 29 - JULY 3, 2024

HILTON BOSTON PARK PLAZA
BOSTON, USA

FINAL PROGRAM

WWW.EBV.KSVIRUS.ORG

THANKS TO OUR SPONSORS!

Gold Sponsor:

GSK

BURROUGHS
WELLCOME
FUND 

 **MERCK**

moderna®

 **viracta**

National Cancer Institute, NIH Grant

Funding for this conference was made possible (in part) by 1R13CA294854-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Journal Sponsors:



BOSTON 2024

TABLE OF CONTENTS

Welcome	2
Committees	3-5
Session Moderators	6-7
Student Abstract Awards	8
Meeting Policy, Safety Plan	9-10
General Information	11-12
Program Schedule & Oral Presentations	13-33
Saturday	13-14
Sunday	14-20
Monday	20-25
Tuesday	26-32
Wednesday	32-33
Poster Presentations 1	34-39
Poster Presentations 2	39-43
Program-at-a-Glance	44



Dear Colleagues,

We are excited to welcome you to Boston for the *International Symposium on EBV & KSHV & Related Agents and Diseases – 3rd Joint Meeting!* What an exciting year for this joint symposium, which will take place on the *60th and 30th anniversaries of the discoveries of EBV and KSHV, respectively.* This joint meeting will bring together researchers studying the oncogenic gamma-herpesviruses EBV and KSHV, as well as related agents, including murine gammaherpesvirus-68. Sessions will highlight viral pathogenesis, viral latency and reactivation, viral gene expression and replication, host responses to infection and autoimmunity, epidemiology, vaccine development, and therapeutic intervention.

The EBV / KSHV 2024 scientific advisory board (SAB) has formulated an innovative and thematic program for researchers interested in EBV and/or KSHV.

Our conference setting in Boston brings a vibrant fusion of history, culture, and summer festivities! With its blend of historical significance, cultural vibrancy, and summer festivities, Boston promises an unforgettable experience for conference attendees.

Sincerely,

EBV-KSHV Local Organizing Committee

- Benjamin E. Gewurz, Brigham & Women’s Hospital and Harvard Medical School, USA (Co-Chair)
- Kenneth M. Kaye, Brigham and Women’s Hospital and Harvard Medical School, Infectious Disease, USA (Co-Chair)
- Ann M. Moormann, UMass Chan Medical School, USA
- Mandy Muller, University of Massachusetts, USA
- Erle S. Robertson, Perelman School of Medicine, University of Pennsylvania, USA
- Bo Zhao, Brigham and Women’s Hospital, Department Medicine, USA



EBV-KSHV Local Organizing Committee

- **Benjamin E. Gewurz**, Brigham & Women's Hospital and Harvard Medical School, USA (Co-Chair)
- **Kenneth M. Kaye**, Brigham and Women's Hospital and Harvard Medical School, Infectious Disease, USA (Co-Chair)
- **Ann M. Moormann**, UMass Chan Medical School, USA
- **Mandy Muller**, University of Massachusetts, USA
- **Erle S. Robertson**, Perelman School of Medicine, University of Pennsylvania, USA
- **Bo Zhao**, Brigham and Women's Hospital, Department Medicine, USA

Scientific Advisory Board

- **Richard F. Ambinder**, Johns Hopkins Medical School, USA
- **Eleni Anastasiadou**, Università di Roma La Sapienza, Italy
- **Alberto Ascherio**, Harvard TH Chan School of Public Health, Harvard Medical School, USA
- **Sumita Bhaduri-McIntosh**, University of Florida, USA
- **Qiliang Cai**, Fudan University, School of Basic Medical Science, P.R.China
- **Ethel Cesarman**, Weill Cornell Medical College, USA
- **Mei-Ru Chen**, Taiwan University, (NTU)
- **Alan Kwok Shing Chiang**, University of Hong Kong, China
- **Jeffrey Cohen**, NNIH, NIAID/DIR, NIH, USA
- **Nicholas Conrad**, University of Texas Southwestern, USA
- **Jennifer Corcoran**, University of Calgary, Canada
- **Blossom Damania**, University of North Carolina Chapel Hill, USA
- **Henri-Jacques Delecluse**, German Cancer Research Center, Germany
- **Hongyu Deng**, Chinese Academy of Sciences, China
- **Alison Didychuk**, Yale University, USA
- **Dirk Dittmer**, University of North Carolina Chapel Hill, USA
- **Paul Farrell**, Imperial College, UK
- **Pinghui Feng**, University of South Carolina, USA
- **Erik Flemington**, Tulane University School of Medicine, USA
- **Craig Forrest**, University of Arkansas, USA
- **Lori Frappier**, University of Toronto, Canada
- **Marta Gaglia**, University of Wisconsin Madison, USA
- **Shou-Jiang (SJ) Gao**, University of Pittsburgh School of Medicine, USA
- **Britt Glaunsinger**, University of California Berkeley, USA
- **Eva Gottwein**, Northwestern University, USA
- **Henry Gruffat**, University of Lyon, France
- **Adam Grundhoff**, Leibniz Institute of Virology, Germany

- **Wolfgang Hammerschmidt**, Helmholtz Center, Germany
- **Meaghan Hancock**, Oregon Health and Science University, USA
- **Yasuaki Harabuchi**, Asahikawa Medical College, Japan
- **Young-Kwon Hong**, USC Keck School of Medicine, USA
- **Yoshihiro Izumiya**, University of California Davis, USA
- **Hem Chandra Jha**, Indian Institute of Technology Indore, India
- **Wei-Hua Jia**, Sun Yat-Sen Cancer Center, P.R. China
- **Dong-Yan Jin**, University of Hong Kong, Hong Kong
- **Eric Johannsen**, University of Wisconsin Madison, USA
- **Jae Jung**, Lerner Research Institute, Cleveland Clinic, USA
- **Teru Kanda**, Tohoku Medical and Pharmaceutical University, Japan
- **John Karjolic**, Vanderbilt University Medical Center, USA
- **Shannon Kenney**, University of Wisconsin Madison, USA
- **Rajiv Khanna**, Queensland Institute of Medical Research, Australia
- **Arnd Kieser**, Helmholtz Center Munich, Germany
- **Hiroshi Kimura**, Nagoya University, Japan
- **Leah Kottyan**, Cincinnati Children's Hospital, USA
- **Laurie Krug**, Center for Cancer Research, NCI, NIH, USA
- **Ke Lan**, Wuhan University, China
- **Michael Lagunoff**, University of Washington, USA
- **Lorenzo Leoncini**, University of Siena, Italy
- **Renfeng Li**, University of Pittsburgh, USA
- **Paul Lieberman**, The Wistar Institute, USA
- **Kwok Wai Lo**, The Chinese University of Hong Kong, China
- **Richard Longnecker**, Northwestern University Medical School, USA
- **Micah Luftig**, Duke Medical School, USA
- **Mark Manzano**, University of Arkansas for Medical Sciences, USA
- **Jeff Martin**, University of California San Francisco, USA
- **Olivia Martinez**, Stanford University School of Medicine, USA
- **George Miller**, Yale University, USA
- **Ashlee Moses**, Oregon Health Sciences University, USA
- **Christian Munz**, University of Zurich, Switzerland
- **Takayuki Murata**, Fujita Health University, Japan
- **Paul Murray**, University of Limerick, Ireland
- **Javier Gordon Ogembo**, City of Hope, USA
- **Sidney Ogolla**, Kenya Medical Research Institute, Kenya
- **Päivi Ojala**, University of Helsinki, Finland
- **Nancy Raab-Traub**, University of North Carolina, USA
- **Ramya Ramaswami**, NCI, National Institutes of Health, USA
- **Rolf Renne**, University of Florida, USA

- **Rosemary Rochford**, University of Colorado Anschutz School of Medicine, USA
- **Cyprian Rosetto**, University of Nevada Reno, USA
- **Abhik Saha**, Presidency University, India
- **Clare Sample**, Penn State Medical Center, USA
- **Jeffery Sample**, Penn State College of Medicine, USA
- **Thomas Schulz**, Institute of Virology, Hannover Medical School, Germany
- **Rona Scott**, Louisiana State University, USA
- **Claire Shannon-Lowe**, University of Birmingham, UK
- **Neelam Sharma-Walia**, Rosalind Franklin University, USA
- **Rebecca Skalsky**, Oregon Health & Science University, USA
- **Bill Sugden**, University of Wisconsin Madison, USA
- **Sankar Swaminathan**, University of Utah, USA
- **Vera Tarakanova**, Medical College of Wisconsin, USA
- **Graham Taylor**, University of Birmingham, UK
- **Italo Tempera**, Wistar Institute, USA
- **Zsolt Toth**, University of Florida, USA
- **Jennifer Totonchy**, Chapman University, USA
- **Jessica M. Tucker**, University of Iowa Carver College of Medicine, USA
- **Linda van Dyk**, University of Colorado Anschutz School of Medicine, USA
- **Subhash Verma**, University of Nevada, USA
- **Matt Weirauch**, Cincinnati Children's Hospital, USA
- **Michelle West**, University of Sussex, UK
- **Denise Whitby**, Frederick National Laboratory for Cancer Research, USA
- **Rob White**, Imperial College London, UK
- **Charles Wood**, LSU Health Sciences Center, USA
- **Ting-Ting Wu**, University of California Los Angeles, USA
- **Miao Xu**, Sun Yat-sen University Cancer Center, China
- **Robert Yarchoan**, National Cancer Institute, USA
- **Lawrence S. Young**, University of Warwick, UK
- **Yan Yuan**, University of Pennsylvania, USA
- **Musheng Zeng**, Sun Yat-Sen University, China
- **Zhi-Ming Zheng**, Center for Cancer Research, NCI, NIH, USA
- **Fanxiu Zhu**, Florida State University, USA
- **Joseph Ziegelbauer**, HIV and AIDS Malignancy Branch, NCI, USA


Meeting Manager

Joan Oefner, Rhema Association Management www.societymanagement.com

Session Moderators

- **Eleni Anastasiadou**, Sapienza university of Rome, Italy
- **Paola Chabay**, Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP). CONICET-GCBA, Argentina
- **Jennifer Corcoran**, University of Calgary, Canada
- **Xinghong Dai**, Case Western Reserve University, United States
- **Allison Didychuk**, Yale University, United States
- **Marta Gaglia**, University of Wisconsin Madison, United States
- **Benjamin Gewurz**, Brigham & Women's Hospital and Harvard Medical School, United States
- **Eva Gottwein**, Northwestern University, United States
- **Rui Guo**, Tufts University, United States
- **Sizun Jiang**, BIDMC/Harvard Medical School, United States
- **John Karjolic**, Vanderbilt University Medical Center, United States
- **Kenneth Kaye**, Brigham and Women's Hospital, Harvard Medical School, United States
- **Arnd Kieser**, Helmholtz Center Munich - German Research Center for Environmental Health, Germany
- **Leah Kottyan**, Cincinnati Children's, United States
- **Laurie Krug**, National Cancer Institute, United States
- **Renfeng Li**, University of Pittsburgh, United States
- **Zhen Lin**, Tulane University Health Sciences Center, United States
- **Zhe Ma**, University of Florida, United States
- **Mark Manzano**, University of Arkansas for Medical Sciences, United States
- **Andrew McGuire**, Fred Hutch Cancer Center, United States
- **Michael McIntosh**, University of Florida, Pediatrics, United States
- **JJ Miranda**, Barnard College, Columbia University, United States
- **Ann Moormann**, Univ of Massachusetts Chan Med Sch, United States
- **Mandy Muller**, UMass Amherst, United States
- **Shunbin Ning**, East Tennessee State University, United States
- **Javier Ogembo**, Beckman Research Institute of City of Hope, United States
- **Sidney Ogolla**, Kenya Medical Research Institute, Kenya
- **Bernadett Papp**, University of Florida, United States
- **Zhiqiang Qin**, University of Arkansas for Medical Sciences, United States
- **Ramya Ramaswami**, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, United States
- **Erle Robertson**, Perelman School of Medicine, University of Pennsylvania, USA
- **Arunava Roy**, University of South Florida, United States
- **Yoshitaka Sato**, Nagoya University Graduate School of Medicine, Japan
- **Kathy Shair**, University of Pittsburgh, United States

- **Meir Shamay**, Azrieli Faculty of Medicine, Bar-Ilan University, Israel
- **Claire Shannon-Lowe**, The University of Birmingham, United Kingdom
- **Neelam Sharma-Walia**, Rosalind Franklin University of Medicine and Science, United States
- **Rebecca Skalsky**, VGTI, United States
- **Italo Tempera**, The Wistar Institute, United States
- **Zsolt Toth**, University of Florida, United States
- **Jennifer Totonchy**, Chapman University, United States
- **Jessica Tucker**, University of Iowa, United States
- **Nate Ungerleider**, Tulane University School of Medicine, United States
- **Chong Wang**, University of Minnesota, United States
- **Matthew Weirauch**, Cincinnati Children's Hospital, United States
- **Michelle West**, University of Sussex, United Kingdom
- **Rob White**, Imperial College London, United Kingdom
- **Christopher Whitehurst**, New York Medical College, United States
- **Miao Xu**, Sun Yat-sen University Cancer Center, China
- **Jun Zhao**, Cleveland Clinic Florida Research and Innovation Center, United States
- **Qian Zhong**, Sun Yat-sen University Cancer Center, China
- **Jian Zhu**, Ohio State University, United States



Student Abstract Awards

- **María Eugenia Amarillo**, (IMIPP), Argentina
- **Michelle Böni**, Switzerland
- **Beniah Brumbaugh**, United States
- **Guo-Long Bu**, Sun Yat-Sen University Cancer Center, China
- **Danielle Burner**, Duke University, United States
- **Jonathan Calero-Landa**, City of Hope, United States
- **Ashley Campbell**, University of Toronto, Canada
- **Alejandro Casco**, University of Wisconsin-Madison, United States
- **Catarina Costa**, Católica Biomedical Research Centre, Portugal
- **Nicholas Doak**, Yale University, United States
- **Sheila Gonzalez**, University of Iowa, United States
- **Mariel Kleer**, University of Calgary, Canada
- **Emmily Koech**, Kenya Medical Research Institute, Kenya
- **Rachael Kostelecky**, University of Colorado, United States
- **Ciara Leahy**, University of Limerick, Ireland
- **Davide Maestri**, The Wistar Institute, United States
- **Christian McDonald**, University of Miami, United States
- **Mahina Tabassum Mitul**, University of California Irvine, United States
- **Steven Mrurdock Jr**, University of Arkansas for Medical Sciences, United States
- **Uwesu Muki**, Muhimbili University of Health and Allied Sciences, United Republic of Tanzania
- **Nilabja Roy Chowdhury**, Bar-Ilan University, Israel
- **Febri Sugiokto**, University of Pittsburgh, United States
- **Iyabode Tiamiyu**, Fred Hutch Cancer Center, United States
- **Krista Tuohinto**, University of Helsinki, RPU, CAN-PRO, Finland
- **Beatriz Veronese**, University of Florida, United States
- **Alexa Wilson**, Dalhousie University, Canada
- **Zhenyu Wu**, Ohio State University, United States
- **Jia Xie**, University of Hong Kong, Hong Kong
- **Wajid Zakir**, Chapman University, United States
- **Travis Zeigler**, United States
- **Zhaoqin Zhang**, University of Birmingham, United Kingdom
- **Ling Zhong**, Sun Yat-sen University, China

CONGRATULATIONS TO ALL THE STUDENT ABSTRACT AWARD WINNERS!

Meeting Policy, Safety Plan

The organizers of the 2024 Joint Epstein-Barr Virus/Kaposi's Sarcoma Associated Herpesvirus Symposia is committed to provide a safe environment for all attendees. The venue is the Hilton Park Plaza Hotel in Boston, which is accessible to those with disabilities and has up to date compliance with safety codes and accessibility for all attendees.

We encourage transparent intellectual debate in a welcoming and inclusive, and safe environment and atmosphere. Organizers and session chairs will foster rigorous but courteous exchanges of all science presented in the oral and poster presentations, in a manner that is respectful to all conferees. The conference is focused on scientific exchange, and is not a platform for political expression. The conference will not tolerate unprofessional behavior including harassment of any kind. Specifically, no sexual, racial, ethnic, or religious harassment or discrimination will be tolerated.

To report any violation of the conference code of conduct, attendees will report violations to any of the local organizing committee members (Drs. Gewurz, Kaye, Moormann, Muller, Robertson, Zhao) who will all be present at the meeting, and the allegation will be kept confidential to the extent possible. Following report of a violation, Drs. Gewurz, Kaye, Moormann, Muller, Robertson will meet to discuss the allegation and any evidence and make a decision as to whether the code of conduct has been violated. Those found in violation will be confidentially informed of the violation. Depending on the level of conduct violation, those in violation will either be given a one-time warning, or will be asked to depart the meeting.

Any attendee who has questions or concerns can approach any of the local organizers, Drs. Gewurz, Kaye, Moormann, Muller, Robertson or Zhao, who will respond to the question or concern and also report it to the other organizers. The conference safety plan will be posted on the meeting website and cited in the abstract book. Reports of any violations will be recorded in written form by the conference organizers, along with a record of the resulting action for enforcement of conference policy.

Although not anticipated, for those with a Civil Rights concern, reports to the Department of Health and Human Services (HHS) Office of Civil Rights (OCR) will be available and the website <https://www.hhs.gov/civil-rights/filing-a-complaint/index.html> will be posted with the conference policy. Filing a complaint of discrimination with the conference organizers is not required prior to filing a discrimination complaint with HHS OCR. Further, seeking any assistance from the conference organizers in no way prohibits filing complaints







with HHS OCR. Please see

<https://grants.nih.gov/grants/policy/harassment/find-help.htm> for more information. Individuals with questions, concerns or complaints related to any of the civil rights laws are encouraged to contact the HHS Office for Civil Rights, <https://www.hhs.gov/ocr/about-us/contact-us/index.html>

Information regarding how individuals can notify the NIH about any concerns of harassment, discrimination or other inappropriate conduct can be found at <https://www.hhs.gov/ocr/complaints/index.html>

Complaints must be filed within 180 days of when you knew that the act or omission complained of occurred. OCR may extend the 180-day period if you can show “good cause”. To file a Civil Rights Complaint online, open the OCR Complaint Portal and select the type of complaint you would like to file. For any serious adverse behavior that is beyond the ability of the conference organizers to handle, the organizers will work with appropriate personnel at the hotel venue, or otherwise contact the appropriate local authorities. In the event of a medical emergency, medical personnel will be immediately called. The hotel venue is located very close to the Massachusetts General Hospital, which is a major tertiary care medical center. In the event of a disaster, the organizers will confer with appropriate local authorities as to the recommended actions.

EBV-KSHV Local Organizing Committee:

 BENJAMIN E. GEWURZ, MD, PHD, (CO-CHAIR)	 KENNETH M. KAYE, MD (CO-CHAIR)
 ANN M. MOORMANN, PHD, MPH	 MANDY MULLER, PHD
 ERLE S. ROBERTSON, PHD	 BO ZHAO, PHD

General Information

Abstracts

Please use the Oxford Abstracts online program to search and view abstracts. All meeting participants are encouraged to include a profile image and opt-in to the networking features to chat or message participants. Any changes to the program or abstracts made after the June 17th print deadline will be reflected in the online program.

ePoster Gallery

Please view the online ePoster gallery with pdf versions of the posters of participating authors. There's still time for poster authors to upload a one-page pdf of their posters, which is tied to the online program. Presenters can also include a video presentation and invite meeting participants to visit both the ePosters & in-person poster presentation, share on Twitter **#ebvkshv** and LinkedIn.

In-Person Posters

The poster boards will be set up in the Statler Room by 10:00 AM on Sunday, June 30th. Materials for fixing the posters to the boards will be available. Poster Session 1 presenters should set up their posters after 10 AM on Sunday and remove their posters from the boards immediately after the session ends. Poster Session 2 presenters can set up their posters from 7:30 AM on Monday and should remove their posters from the boards immediately after the session. The boards will be removed on Tuesday morning and must be empty. Poster Presenters should be at their posters during their scheduled poster session, ODD number posters the 1st hour, EVEN number posters the 2nd hour.

Oral Presentations

- All speakers should visit the speaker ready room (Commonwealth Room) at least an hour before scheduled session start time, to view their presentation and make any corrections before uploading from a thumb drive through the network to the appropriate session, with the assistance of the Speaker Ready Room AV Tech. All presentations will be deleted following the session.
- Alternatively, presenters can connect their thumb drive directly into the presentation laptop in their session room, and download presentation during the break before the session, or at least one hour prior to session start time (with the assistance of the AV technician in the room).
- Due to the high number of presentations and potential queue, it is highly recommended to preload presentations in the Commonwealth Room, an AV technician will be available 7 hours a day to assist speakers.

Presentations should be labeled as follows, Program ID_Last name
e.g., **Plenary 2.1_Yeo; Parallel 9.2_Burton; Keynote 2.1_Raab-Traub**

If any presentations include videos with audio, it is HIGHLY recommended to test in speaker ready room at least one hour before the start of the session & inform the AV technician if your presentation includes video with audio.

WiFi Access: Network Name: **ebvkshv** Password: **ebvkshv2024**

Location of Meeting Events

- Opening Session: Terrace Room on Lobby Level Saturday night Only
- Welcome Reception Saturday evening: Statler Room Mezzanine Level
- Plenary Sessions: Grand Ballroom A Mezzanine Level
- Parallel Sessions: Grand Ballroom A and Georgian Room, Mezzanine Level
- Poster Sessions: Statler Room, across from Grand Ballroom
- Coffee Breaks: Grand Ballroom B and Foyer
- Sunday Lunch – Panera Bread and Boston Public Garden
- Monday Lunch – Maggiano’s Little Italy (next door to hotel)
- KSHV 2025 Organization Lunch Monday for those who replied, MJ O’Connor’s at the Hilton
- Tuesday Lunch – Empire Garden in Chinatown
- Tuesday Gala Dinner – For those who registered, Avenue 34 at the Hilton

Continental Breakfast will be Available Every Morning from 7:15 – 8:00 am

There will be a Continental Breakfast (see online program for more details) each morning before the start of the Plenary Sessions. Please be sure to get to the Grand Ballroom area early so you can enjoy a leisurely breakfast or at least grab coffee, protein, fresh fruit and carbs to bring into the meeting room with you before the session begins. There will be coffee, tea and decaf at the mid-morning coffee breaks and coffee and soft-drinks at the afternoon breaks.

Lunches - Lunches have been organized on all three full days of the meeting, outside the hotel (hotel lunches would cost 2/3 more and we hope attendees will enjoy getting out a bit during the lunch breaks).

Welcome Reception & Poster Session Receptions

The food at the Welcome Reception on Saturday evening can be in lieu of dinner (especially for our student participants), and there will be a buffet at Sunday evening’s Poster Session, but Monday’s Poster Session is meant to be an after-dinner event.

Conference Program & Oral Presentations

SATURDAY, JUNE 29, 2024

Onsite Registration & Badge Pickup

3:30 - 7:15pm Saturday, 29th June

Room Terrace Room Foyer

Please stop by the registration desk to pick-up your meeting badge. We will also be able to take last minute onsite registrations.

Welcome & Introductions

5:00 - 5:15pm Saturday, 29th June

Room Terrace Room

Moderators Benjamin Gewurz, Kenneth Kaye

Plenary Session 1 Coinfection

5:15 - 7:15pm Saturday, 29th June

Terrace Room

Moderators Paola Chabay, Zsolt Toth

17:15 - 17:30 **Plenary 1.1 Epstein Barr Virus Synergizes with Plasmodium falciparum Malaria to Induce Aberrant Expression of Activation-Induced Cytidine Deaminase: Implications for Burkitt's lymphoma**, [Bonface Ariera](#)

17:30 - 17:45 **Plenary 1.2 The Protective Effect of Gammaherpesvirus on the Malaria lethality in Mouse Model.**, [Viriato M'Bana](#)

17:45 - 18:00 **Plenary 1.3 Repurposed Nitroxoline Inhibits Models of EBV- and KSHV-Associated Malignancies without HIV Reactivation**, [JJ Miranda](#)

18:00 - 18:15 **Plenary 1.4 High-resolution Antibody Profiling of KSHV-infected Individuals Presenting with and without Kaposi Sarcoma Reveals Distinct Viral-Exposure Signatures**, [Dicle Yalcin](#)

18:15 - 18:30 **Plenary 1.5 Role of HERV-K Np9 protein in KSHV-associated malignancies**, [Zhiqiang Qin](#)

18:30 - 18:45 **Plenary 1.6 A Persistent CD8+ HIV-Specific T-Cell Response in KS Tumors from Adults with HIV Despite Anti-Retroviral Therapy**, [Iyabode Tihamiyu](#)

18:45 - 19:00 **Plenary 1.7 Revealing the complexity of EBV type 1 and type 2 infection kinetics in a longitudinal study of Kenyan children**, [Sin Ting Hui](#)

19:00 - 19:15 **Plenary 1.8 KSHV Cooperates with EBV to Transform B Cells and Drive Lymphomagenesis**, [Mitch Hayes](#)

Welcome Reception

7:15-8:45pm Saturday, 29 June

Statler Room on the Mezzanine Level

Join us for the Welcome Reception, please pickup your badge first at the Terrace Room Registration Desk before 7:15 PM

SUNDAY, JUNE 30, 2024

Continental Breakfast & Registration

7:15 - 8:00am Sunday, 30th June

Grand Ballroom B & Ballroom Foyer

Plenary Session 2 Tumor Microenvironment

8:00 - 10:00am Sunday, 30th June

Grand Ballroom A

Moderators Eleni Anastasiadou, Eva Gottwein

08:00 - 08:15 **Plenary 2.1 Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation Within the Classic Hodgkin Lymphoma Tumor Microenvironment**, [Yao Yu Yeo](#)

08:15 - 08:30 **Plenary 2.2 Spatial Characterisation of Immune Checkpoint Expressing CD8+ T-cell Subsets in Nasopharyngeal Carcinoma**, [Graham Taylor](#)

08:30 - 08:45 **Plenary 2.3 Multi-omic spatial profiling of the tumour microenvironment reveals correlates of malignant behavior in EBV-positive Hodgkinoid lymphoproliferations**, [Matthew Pugh](#)

08:45 - 09:00 **Plenary 2.4 Spatially-Informed Prediction of HIV-Associated Non-Hodgkin Lymphoma Vulnerabilities by EBV Infection and Cell of Origin**, [Elliott SoRelle](#)

09:00 - 09:15 **Plenary 2.5 Expression Cloning Discovery of KSHV Epitopes Recognized by KS CD8+ Tumor Infiltrating Lymphocytes**, [Iyabode Tihamiyu](#)

09:15 - 09:30 **Plenary 2.6 High Dimensional, Single Cell Analysis of EBV-Specific T Cells from Pediatric Transplant Recipients with Elevated EBV DNAemia or Controlled Infection**, [Edward Vizcarra](#)

09:30 - 09:45 **Plenary 2.7 Burkitt Lymphoma: The DARKEst Lymphoma Microenvironment**, [Maria Chiara Siciliano](#)

09:45 - 10:00 **Plenary 2.8 An Immunosuppressive Tumour Microenvironment, and not a Loss of Systemic Immunity to EBV Latent Antigens, Underpins the Pathogenesis of EBV-Positive Diffuse Large B-Cell Lymphoma, Éanna Fennell**

Coffee Break

10:00 - 10:30am Sunday, 30th June
Grand Ballroom B & Ballroom Foyer

Keynote Address I: Addressing latent viral infection in KS and lymphoma

Ethel Cesarman, Weill Cornell, USA

10:30 - 11:00am Sunday, 30th June

Grand Ballroom A - Moderator Kenneth Kaye



BOSTON 2024

Professor Ethel Cesarman

KSHV Keynote Talk at EBV-KSHV Joint Meeting



Professor Cesarman's laboratory at Weill Cornell Medical College is involved in studying the process of viral oncogenesis in human cancer. She is co-PI on a five-year, \$4.2 million grant by the National Cancer Institute, part of the National Institutes of Health, to investigate the molecular mechanisms by which immune cells called B cells interact with Epstein-Barr virus (EBV) to cause lymphoma, particularly in people living with HIV.

Parallel Session 3 Epigenetics, Gene Expression and Reactivation I

11:00am - 1:00pm Sunday, 30th June

Grand Ballroom A

Moderators John Karijovich, Renfeng Li

11:00 - 11:15 **Parallel 3.1 Regulation of KSHV latent chromatin by host inflammatory signaling via transcription memory, Yoshihiro Izumiya**

11:15 - 11:30 **Parallel 3.2 Natural Sequence Variation in Essential Epstein-Barr Virus Replication Factor EBNA1 Preserves Key Interfaces and Can Enhance Sensitivity to Inhibitors, Michelle West**

11:30 - 11:45 **Parallel 3.3 High-density Resolution of the KSHV Transcriptome Identifies Novel Transcript Isoforms Generated by Long-range Transcription and Alternative Splicing, Ritu Shekhar**

11:45 - 12:00 **Parallel 3.4 Regulation of EBV latent episomes by histone variant H2A.Z**, [Leonardo Castro-Muñoz](#)

12:00 - 12:15 **Parallel 3.5 A Short Linear Motif in KSHV ORF45 is Crucial for its Interaction with Members of the Host FOXK Transcription Factor Subfamily, which are Essential for the KSHV Lytic Cycle**, [Bernadett Papp](#)

12:15 - 12:30 **Parallel 3.6 Viral vIRF3 Cooperates with Cellular IRF4 to Drive IRF4 Super-Enhancer Activity through a Complex DNA Element**, [Ziyan Liang](#)

12:30 - 12:45 **Parallel 3.7 From Enhancers to Genome Conformation: Complex Transcriptional Control of a Single Herpesviral Gene**, [David Morgens](#)

12:45 - 13:00 **Parallel 3.8 Transcriptome Analysis of Burkitt Lymphoma cells treated with Anti-convulsant drugs that are Inhibitors of Epstein–Barr Virus Lytic Reactivation**, [Kelly Gorre](#)

Parallel Session 4 Innate and Adaptive Immunity I: Viral Evasion

11:00am - 1:00pm Sunday, 30th June

Georgian Room

Moderators Arunava Roy, Claire Shannon-Lowe, Shunbin Ning

11:00 - 11:15 **Parallel 4.1 KSHV MicroRNA-Mediated Repression of STING**, [Kimberly Paulsen](#)

11:15 - 11:30 **Parallel 4.2 Phenotype and tissue distribution of EBV specific immune control**, [Christian Münz](#)

11:30 - 11:45 **Parallel 4.3 The combination of proviral and antiviral roles of B cell-intrinsic STAT1 expression defines parameters of chronic gammaherpesvirus infection**, [Vera Tarakanova](#)

11:45 - 12:00 **Parallel 4.4 Kaposi Sarcoma-Associated Herpesvirus Induces Protective T Cell Responses in a Pre-Clinical in vivo Model**, [Michelle Böni](#)

12:00 - 12:15 **Parallel 4.5 Diminished Defenders: CD56neg NK cells limited impact on rituximab-mediated antibody dependent cell cytotoxicity against Burkitt lymphoma**, [Catherine Forconi](#)

12:15 - 12:30 **Parallel 4.6 Application of Epstein Barr Virus Proteome Microarrays to Characterize Humoral Immune Responses and Define Immune Signatures for Risk of EBV-Associated Cancers**, [Denise L. Doolan](#)

12:30 - 12:45 **Parallel 4.7 Potential Shift in Immunological Frontlines: Deviation of Cellular Recognition Strategies by NK and Gamma Delta T Cells in Endemic Burkitt Lymphoma**, [Zachary Racenet](#)

12:45 - 13:00 **Parallel 4.8 Homozygous ZAP70 mutations in a patient with EBV B cell lymphoproliferative disease, Jeffrey Cohen**

Lunch Break - Panera Bread 115 Stuart Street (at Tremont)

1:00 - 2:45pm Sunday, 30th June




During Sunday's lunch break take a 6 minute walk to Panera Bread to pickup a box lunch



Across from the Panera bread is Boston's famous Public Garden and Boston Commons parks where we hope the weather will cooperate and attendees can enjoy al fresco dining.

The Boston Public Garden and Boston Commons is just a few blocks from the Panera Bread where we hope attendees can enjoy their sandwiches and some fresh air and networking. If anyone needs meeting staff to pick-up their lunches and bring them back to the hotel, please just ask at the registration desk.



EBV Association Board Meeting/Lunch

1:00 – 2:45pm Sunday, 30th June

Hancock Room

Parallel Session 5 Epigenetics, Gene Expression and Reactivation II

2:45 - 4:45pm Sunday, 30th June

Grand Ballroom A

Moderators Yoshitaka Sato, JJ Miranda

14:45 - 15:00 **Parallel 5.1 The EBV B-cell Lytic Switch**, [Zhixuan Li](#)

15:00 - 15:15 **Parallel 5.2 EBV reprograms chromatin loop extrusion to support cell proliferation**, [Italo Tempera](#)

15:15 - 15:30 **Parallel 5.3 KSHV genome harbors both constitutive and lytically induced enhancers**, [Nilabja Roy Chowdhury](#)

15:30 - 15:45 **Parallel 5.4 Functional Characterization of Epstein-Barr Virus encoded Inc-BARTs in Associated Tumors**, [Honglin Chen](#)

15:45 - 16:00 **Parallel 5.5 Kaposi's sarcoma herpesvirus latency-associated nuclear antigen is a bimodal regulator of viral gene expression and essential for lytic infection**, [Nicholas Van Sciver](#)

16:00 - 16:15 **Parallel 5.6 KSHV Genome Becomes Refractory to the Binding and Lytic Cycle Driving Activity of HIF-1 α during De Novo KSHV Infection**, [Zsolt Toth](#)

16:15 - 16:30 **Parallel 5.7 Gammaherpesvirus Induced Retrotransposon Activation Drives mRNA Isoform Switching**, [Azra Lari](#)

16:30 - 16:45 **Parallel 5.8 Hypoxic Reactivation of Kaposi's Sarcoma Associated Herpesvirus: The art of Manipulating Host Machinery by KSHV**, [Rajnish Singh](#)

Parallel Session 6 Lytic Cycle/Viral Replication/Reactivation I

2:45 - 4:45pm Sunday, 30th June

Georgian Room

Moderators Rebecca Skalsky, Zhe Ma, Bernadett Papp

14:45 - 15:00 **Parallel 6.1 Remodeling of the ribosomal quality control and integrated stress response by viral ubiquitin deconjugases**, [Jiangnan Liu](#)

15:00 - 15:15 **Parallel 6.2 Targeting the OTUD4-USP7 Deubiquitinase Complex to Curb KSHV Lytic Reactivation**, [Junjie Zhang](#)

15:15 - 15:30 **Parallel 6.3 EBV BGLF4 Kinase is Packaged into the Extracellular Vesicles and Regulates the Constituents inside to Facilitate Virus Infection**, [Mei-Ru Chen](#)

15:30 - 15:45 **Parallel 6.4 The KSHV E3 Ubiquitin Ligase K3 Regulates the Unfolded Protein Response**, [Alexa Wilson](#)

15:45 - 16:00 **Parallel 6.5 Gene Expression Profiling and Genomic Analysis of Synthetic Lethal Sensitive and Resistant Cell Lines Derived from EBV+ and EBV- Diffuse Large B-cell Lymphomas**, Michael McIntosh

16:00 - 16:15 **Parallel 6.6 IFI16 recruits HDAC1 and 2 to deacetylate the KSHV Latency-Associated Nuclear Antigen (LANA), promoting latency**, Arunava Roy

16:15 - 16:30 **Parallel 6.7 Aquaporin 3 (AQP3) regulates oxidative stress and the life cycle of Kaposi sarcoma Herpesvirus (KSHV) in its associated cancers**, Neelam Sharma-Walia

16:30 - 16:45 **Parallel 6.8 DDX5 and DDX17 Facilitate Lytic Reactivation of Gammaherpesviruses**, Praneet Kaur Sandhu

Coffee Break

4:45 - 5:00pm Sunday, 30th June

Grand Ballroom B & Ballroom Foyer

Keynote Address II Elliott Kieff Memorial Lecture: Elliott Kieff and The Foundations of EBV Molecular Biology

Nancy Raab-Traub, UNC-Chapel Hill, USA

5:00 - 5:30pm Sunday, 30th June

Grand Ballroom A - Moderator: Erle Robertson



BOSTON 2024

Professor Nancy Raab-Traub

Elliott Kieff Lecture at EBV-KSHV
Joint Meeting



Professor Elliott Dan Kieff, MD, PhD January 4, 2024, Harvard University - A leading scholar in the field of Human Virology, who made seminal discoveries concerning the mechanisms by which EBV causes infectious mononucleosis and contributes to human malignancies, improving science and global public health.*

In Memoriam

5:30 - 5:45pm Sunday, 30th June

Grand Ballroom A

GEORGE SAI WAH TSAO, PhD

(10/28/1955 - 12/08/2022)

Poster Session 1

5:45 - 7:45pm Sunday, 30th June
Statler Room

Presenters will be at their posters as follows: Visit the ODD number Posters from 5:45 - 6:45 PM and the EVEN number Posters from 6:45 - 7:45 PM. Food & Beverage and Bars will be setup in Grand Ballroom B and the Ballroom Foyer

MONDAY, JULY 1, 2024

Continental Breakfast

7:15 - 8:00am Monday, 1st July
Grand Ballroom B & Ballroom Foyer

Plenary Session 7 Transformation/oncogenesis I

8:00 - 10:00am Monday, 1st July
Grand Ballroom A
Moderators Mark Manzano, Arnd Kieser

08:00 - 08:15 **Plenary 7.1 The complete Kaposi Sarcoma-associated herpesvirus genome induces early-onset, metastatic angiosarcoma in transgenic mice,** Dirk Dittmer

08:15 - 08:30 **Plenary 7.2 Latent membrane protein 2A (LMP2A) determines dependence on antigen-induced signaling in Epstein-Barr virus (EBV) transformed lymphoblastoid cells,** Makoto Ohashi

08:30 - 08:45 **Plenary 7.3 Matched molecular clones of KSHV and EBV for functional analysis of viral cooperation,** Jan Knickmann

08:45 - 09:00 **Plenary 7.4 Single Cell Analysis of KSHV-induced Loss of Contact Inhibition in a Lymphatic Endothelial Cell Model of Kaposi's Sarcoma,** Eva Gottwein

09:00 - 09:15 **Plenary 7.5 Suppression of IRF6 Expression Promotes the Development of EBV+ Nasopharyngeal Carcinoma (NPC) by Inhibiting Epithelial Cell Differentiation and Preventing EBV Lytic Reactivation,** Shannon Kenney

09:15 - 09:30 **Plenary 7.6 The LMP1-induced Phosphoproteome is Efficiently Targeted by Novel Small Molecule LMP1-TRAF2 Interaction Inhibitors in LCLs,** Arnd Kieser

09:30 - 09:45 **Plenary 7.7 Unveiling the Role of FAM50A in KSHV-Mediated RNA Splicing Alterations and Cellular Transformation**, [Shou-Jiang Gao](#)

09:45 - 10:00 **Plenary 7.8 Polymerase Theta is a Synthetic Lethal Target for Killing Epstein-Barr Virus Lymphomas**, [Sumita Bhaduri-McIntosh](#)

Coffee Break

10:00 - 10:30am Monday, 1st July
Grand Ballroom B & Ballroom Foyer

Keynote Address III: Exploring the Druggability of two Key KSHV Proteins Required for Viral Persistence and Inflammation

Thomas Schulz, Hannover Medical School, Germany

10:30 - 11:00am Monday, 1st July

Grand Ballroom A - Moderator: Mandy Muller



BOSTON 2024

**Professor Thomas
Schultz**
**KSHV Keynote Talk at
EBV-KSHV Joint Meeting**



Thomas Schulz, Institute of Virology, Hannover Medical School, to give KSHV Keynote at EBV-KSHV Joint Meeting. Prof. Schulz is head of the Institute of Virology at the Hannover Medical School in Hannover, Germany, since 2000.

Parallel Session 8 Transformation/oncogenesis II

11:00am - 1:00pm Monday, 1st July

Grand Ballroom A

Moderators Meir Shamay, Kathy Shair

11:00 - 11:15 **Parallel 8.1 EBNA-LP Cooperates with YY1 in Promoting B Cell Transformation Through Changes in Chromatin Architecture**, [Davide Maestri](#)

11:15 - 11:30 **Parallel 8.2 Epstein-Barr Virus Protein EBNA-LP Reduces Innate Anti-Viral Sensing and Inhibits SP140L, a Novel Restriction Factor of Herpesvirus Infection**, [Jana Cable](#)

11:30 - 11:45 **Parallel 8.3 Shared and Distinct Interactions of Type 1 and Type 2 Epstein-Barr Nuclear Antigen 2 with the Human Genome**, [Leah Kottyan](#)

11:45 - 12:00 **Parallel 8.4 Application of Primary effusion lymphoma model mice for developing novel therapeutics**, Seiji Okada

12:00 - 12:15 **Parallel 8.5 The knockout of Epstein-Barr virus lytic gene, BNRF1 causes a fragile growth of both EBV-infected and EBV-transformed cells**, Yoshitaka Sato

12:15 - 12:30 **Parallel 8.6 KSHV Infection Promotes Mesenchymal-to-Endothelial Transition for Kaposi's Sarcomagenesis**, Yan Yuan

12:30 - 12:45 **Parallel 8.7 Incorporation of Epstein-Barr viral variation implicates significance of LMP1 in survival prediction and prognostic subgrouping in Burkitt lymphoma**, Jeffrey Bailey

12:45 - 13:00 **Parallel 8.8 Ectopic Expression of KSHV miR-K12-9 Can Induce Transformation of immortalized and primary Endothelial Cells**, Lauren Gay

Parallel Session 9 Virus/Host Interactions I

11:00am - 1:00pm Monday, 1st July

Georgian Room

Moderators Marta Gaglia, Chong Wang

11:00 - 11:15 **Parallel 9.1 Epstein-Barr-Virus-Driven Cardiolipin Synthesis Sustains Metabolic Remodeling During B-cell Lymphomagenesis**, Rui Guo

11:15 - 11:30 **Parallel 9.2 EBV Latent Membrane Protein 1 Signaling Alters Cysteine Metabolism to Support Antioxidant Defense and to Protect Infected Cells from Ferroptosis Induction**, Eric Burton

11:30 - 11:45 **Parallel 9.3 TBA**

11:45 - 12:00 **Parallel 9.4 KSHV promotes oncogenic FOS to inhibit nuclease AEN and transactivate RGS2 for AKT phosphorylation**, Vladimir Majerciak

12:00 - 12:15 **Parallel 9.5 KSHV Perturbs Mitochondrial Morphodynamics to Dampen Innate Immune Response for Dissemination**, Ig Zhu

12:15 - 12:30 **Parallel 9.6 Transcriptional Changes Induced by the G Protein-Coupled Receptor of KSHV Reveal Regulation of Multiple Aspects of B Cell Biology**, Anna K. Grosskopf

12:30 - 12:45 **Parallel 9.7 PINLYP regulates KSHV reactivation through cPLA2-mediated phospholipid metabolism**, Xiaozhen Liang

12:45 - 13:00 **Parallel 9.8 Selective autophagy impedes KSHV entry after recruiting the membrane damage sensor galectin-8 to virus-containing endosomes**, Katarina Wendy Schmidt

Lunch Break - Maggiano's Little Italy

1:00 - 2:45pm Monday, 1st July

Maggiano's Little Italy

For Monday's lunch we have reserved the entire Maggiano's Little Italy restaurant which is right next to the Hilton Boston Back Bay.

KSHV 2025 Workshop Organization Lunch Meeting will be held at the same time *for all those who responded to the survey by June 10th*, please go to the MJ O'Connors Restaurant, there is a private room in the back reserved for this lunch meeting.

Parallel Session 10 Virus Host Interactions II

2:45 - 4:45pm Monday, 1st July

Grand Ballroom A

Moderators Neelam Sharma-Walia, Italo Tempera

14:45 - 15:00 **Parallel 10.1 An Epstein-Barr lytic reporter virus reveals extensive host shutoff via BGLF5-independent mechanisms**, [Alejandro Casco](#)

15:00 - 15:15 **Parallel 10.2 Orthogonal CRISPR tiling screens identify viral genes essential for the survival of KSHV-transformed B cells**, [Mark Manzano](#)

15:15 - 15:30 **Parallel 10.3 Latent Epstein-Barr Virus Infection Collaborates with Myc Over-expression in Normal Human B Cells to Induce Burkitt-like Lymphomas in Mice**, [Jillian Bristol](#)

15:30 - 15:45 **Parallel 10.4 Epstein-Barr Virus Tegument Protein BNRF1 Restrains DNA Repair by Targeting Poly(ADP-ribosylation) Status**, [Chih-Ying Lee](#)

15:45 - 16:00 **Parallel 10.5 Identification and Characterization of Kaposi Sarcoma Associated-Herpesvirus Glycoprotein-Specific Neutralizing Antibodies as a Tool to Elucidate Mechanisms of Viral Transmission**, [Jonathan Calero-Landa](#)

16:00 - 16:15 **Parallel 10.6 Genome-wide CRISPR/Cas9 screen identifies TIM1 and TIM4 as host factors for Kaposi's sarcoma-associated herpesvirus (KSHV) and the related rhesus monkey rhadinovirus (RRV)**, [Alexander Hahn](#)

16:15 - 16:30 **Parallel 10.7 Intrinsic p53 Activation Restricts GHV-Driven Germinal Center B Cell Expansion during Latency Establishment**, [Shana Owens](#)

16:30 - 16:45 **Parallel 10.8 ERBB Family Members Tightly Regulate KSHV Flip from Latency to Lytic Replication**, [Annabel Olson](#)

Parallel Session 11 Autoimmunity including Multiple Sclerosis

2:45 - 4:45pm Monday, 1st July

Georgian Room

Moderators Leah Kottyan, Sizun Jiang

14:45 - 15:00 **Parallel 11.1 Selected T lymphocytes Specific for Autologous Epstein-Barr Virus Infected Cell Lines Are Enriched in Multiple Sclerosis Cerebrospinal Fluid**, John Lindsey

15:00 - 15:15 **Parallel 11.2 Heightened Epstein-Barr Virus Immunity and Potential Cross-Reactivities in Multiple Sclerosis**, Graham Taylor

15:15 - 15:30 **Parallel 11.3 Spontaneous lymphoblastoid cell lines (SLCLs) from patients with active multiple sclerosis (MS) reveal differences in viral and host gene expression relative to healthy controls and conventional LCLs**, Paul Lieberman

15:30 - 15:45 **Parallel 11.4 Anoctamin-2 is Encephalitogenic and is a Target of EBNA1 Adaptive Immune Responses in Multiple Sclerosis**, Olivia Thomas

15:45 - 16:00 **Parallel 11.5 Human studies of Multiple Sclerosis based on human data and biological samples**, Alberto Ascherio

16:00 - 16:15 **Parallel 11.6 Epstein-Barr Virus (EBV) encoded transcription co-factors (TFs) in EBV-infected B cells are strongly associated with the genetic risk loci of Systemic Lupus Erythematosus (SLE), independently, in East Asians (EAS) and Europeans (EU)**, John Harley

16:15 - 16:30 **Parallel 11.7 Exploring the Cellular Origin of Systemic Chronic Epstein-Barr Virus Disease**, Kimitoshi Goto

16:30 - 16:45 **Parallel 11.8 EBNA2 Mechanisms in Autoimmune Diseases**, Matthew T. Weirauch

Coffee Break

4:45 - 5:00pm Monday, 1st July

Grand Ballroom B & Ballroom Foyer

Henle Lecture/Keynote Address IV: An Odyssey to Uncover the Link Between EBV, Malaria and Burkitt Lymphoma

Rosemary Rochford, University of Colorado, USA

5:00 - 5:30pm Monday, 1st July

Grand Ballroom A - Moderator: Benjamin Gewurz



BOSTON 2024

Dr. Rosemary Rochford

receives the Henle Award for major contributions to Epstein-Barr virus research at EBV-KSHV Joint Meeting



*Drs. Gertrude *2006 and Werner Henle *1987, Professors at the Children's Hospital of Philadelphia, were pioneers in tumor virology - co-founders of our present knowledge on infectious agents in human cancers.*

EBV Association Annual Members' Business Meeting

5:30 - 6:30pm Monday, 1st July

Grand Ballroom A

All members of the EBV Association, and other interested in the society, should plan to attend this annual business meeting to hear about the Society's finances, future meetings and membership.

Dinner Break, On Own till 8:00pm

Poster Session 2

8:00- 10:00 pm Monday, 1st July

Statler Room

Presenters will be at their posters as follows: Visit the ODD number Posters from 8:00 – 9:00pm and the EVEN number Posters from 9:00 – 10:00pm. Food & Beverage and Bars will be setup in Grand Ballroom B and the Ballroom Foyer

TUESDAY, JULY 2, 2024

Continental Breakfast

7:15 - 8:00am Tuesday, 2nd July

Grand Ballroom B & Ballroom Foyer

Plenary Session 12 Virus/Host Interactions III

8:00 - 10:00am Tuesday, 2nd July

Grand Ballroom A

Moderators Rob White, Laurie Krug

08:00 - 08:15 **Plenary 12.1 Targeting Cellular Transcription Factors Essential for EBV Replication**, [Sankar Swaminathan](#)

08:15 - 08:30 **Plenary 12.2 Changes in SUMO-modified Proteins upon EBV Reactivation Identifies TRIM24 and TRIM33 as Antiviral Factors and a Novel Role for BZLF1 in Disabling them**, [Lori Frappier](#)

08:30 - 08:45 **Plenary 12.3 Infection of Myeloid cells with MHV68 Reveals Multiple Restriction Points that Limit Productive Lytic Replication.**, [Gabrielle Vragel](#)

08:45 - 09:00 **Plenary 12.4 Macrophages and B cell latency, a possible link between KSHV and malaria?** [Julie Tram](#)

09:00 - 09:15 **Plenary 12.5 The role of TOPBP1 in oriP-dependent EBV latent DNA replication**, [Dong-Yan Jin](#)

09:15 - 09:30 **Plenary 12.6 Retinoblastoma Protein Restriction of E2F Activity is Required for EBV Productive Replication in the Differentiated Epithelium**, [Rona S. Scott](#)

09:30 - 09:45 **Plenary 12.7 Unveiling the Role of KSHV-Infected Human Mesenchymal Stem Cells in Kaposi's Sarcoma Initiation**, [Julian Naipauer](#)

09:45 - 10:00 **Plenary 12.8 Influence of Human and Viral IL-6 on KSHV Infection in Human Tonsil Lymphocytes**, [Wajd Zakir](#)

Coffee Break

10:00 - 10:30am Tuesday, 2nd July

Grand Ballroom B & Ballroom Foyer

Keynote Address V Sir Anthony Epstein Memorial Lecture: EBV sequence variation, disease and vaccination strategies, Professor Paul Farrell, Imperial College London, UK

10:30 - 11:00am Tuesday, 2nd July

Grand Ballroom A - Moderator: Ann Moormann



BOSTON 2024

Professor Paul Farrell

Sir Anthony Epstein Memorial
Lecture at EBV-KSHV Joint
Meeting



Professor Sir Anthony Epstein, May 18, 1921 - February 6, 2024 - Pathologist who discovered the first virus known to cause cancer

Parallel Session 13 Noncoding RNA

11:00am - 12:00pm Tuesday, 2nd July

Grand Ballroom A

Moderators Nate Ungerleider, Jessica Tucker

11:00 - 11:15 **Parallel 13.1 The kaposin RNA transcript is the architect of a successful KSHV infection, Mariele Kleer**

11:15 - 11:30 **Parallel 13.2 Interferon Induced CircRNAs Escape Herpesvirus Host Shutoff and Suppress Lytic Infection, Sarah Dremel**

11:30 - 11:45 **Parallel 13.3 Profiling miRNA changes in EBV lytic infection identifies a function for BZLF1 in upregulating miRNAs from the DLK1-DIO3 locus, Ashley Campbell**

11:45 - 12:00 **Parallel 13.4 Inhibition of Type I Interferon Signaling is a Conserved Function of Gamma-herpesvirus-encoded MicroRNAs, Rebecca Skalsky**

Parallel Session 14 Innate and adaptive immunity II: RNA degradation

11:00am - 12:00pm Tuesday, 2nd July

Georgian Room

Moderators Jun Zhao, Christopher Whitehurst

11:00 - 11:15 **Parallel 14.1 KSHV exploits the TLR3/TRIF pathogen sensing pathway to activate caspases and block type I interferon induction**, [Marta Gaglia](#)

11:15 - 11:30 **Parallel 14.2 MHV68 infection alters tRNA splicing and elicits tRNA cleavage**, [Jessica Tucker](#)

11:30 - 11:45 **Parallel 14.3 RBM25 is a new Restriction Factor against KSHV**, [Guillaume Fiches](#)

11:45 - 12:00 **Parallel 14.4 Evaluation of candidate RNaseH molecules for resistance to viral replication and transcription activator (RTA) to test the role of R-loops during Kaposi's sarcoma-associated herpesvirus (KSHV) infection**, [Julia Fox](#)

Parallel Session 15 Structure

12:00 - 1:00pm Tuesday, 2nd July

Grand Ballroom A

Moderators Xinghong Dai, Allison Didychuk

12:00 - 12:15 **Parallel 15.1 Glycoprotein K8.1 is O-glycosylated in KSHV and K8.1-chimeric RRV**, [Gavin Golas](#)

12:15 - 12:30 **Parallel 15.2 Structural basis for the ligand promiscuity and high signaling activity of KSHV GPCR**, [Dokyun Kim](#)

12:30 - 12:45 **Parallel 15.3 Structure and antigenicity of Kaposi's sarcoma-associated herpesvirus glycoprotein B**, [Cong Sun](#)

12:45 - 13:00 **Parallel 15.4 Structure-Function Studies of EBNA1, a Critical Therapeutic Target for Epstein-Barr Virus-Associated Diseases**, [Troy Messick](#)

Parallel Session 16 Vaccines I: Disease Associations

12:00 - 1:00pm Tuesday, 2nd July

Georgian Room

Moderators Jennifer Totonchy, Miao Xu

12:00 - 12:15 **Parallel 16.1 Predictors of Postviral Symptoms Following Epstein-Barr-Virus-Associated Infectious Mononucleosis in Young People – Data from the IMMUC Study**, [Lorenz Mihatsch](#)

12:15 - 12:30 **Parallel 16.2 A Cocktail Nanovaccine Targeting Key Entry Glycoproteins Elicits High Levels of Neutralizing Antibodies Against EBV Infection**, [Ling Zhong](#)

12:30 - 12:45 **Parallel 16.3 Human Herpesvirus 8 Infection is Associated with Prostate Cancer Among IFNL4-ΔG Carriers**, [Frank Jenkins](#)


12:45 - 13:00 **Parallel 16.4 Different mutational landscape among HHV8/EBV-negative and HHV8- and/or EBV-positive effusion-based lymphomas?** [Margherita Vannucchi](#)

Lunch Break - Empire Garden in Chinatown

1:00 - 3:00pm Tuesday, 2nd July

Empire Garden in Chinatown

Tuesday's Group Lunch: Empire Garden in Chinatown, a 9-minute walk from the Hilton Boston Park Plaza. Empire Garden Restaurant, 690 Washington St, Boston. Please ask at Registration if you need any assistance with transportation.



Parallel Session 17 Vaccines II: Therapeutics, Clinical Care

3:00 - 4:30pm Tuesday, 2nd July

Grand Ballroom A

Moderators Ramya Ramaswami, Javier Ogembo

15:00 - 15:15 **Parallel 17.1 Targeted Eradication of EBV-Positive Cancer Cells by CRISPR/dCas9-Mediated EBV Reactivation in Conjugation with Ganciclovir**, [Renfeng Li](#)

15:15 - 15:30 **Parallel 17.2 Pembrolizumab in HIV-associated Kaposi Sarcoma**, [Kathryn Lurain](#)

15:30 - 15:45 **Parallel 17.3 Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers**, [Man Wu](#)

15:45 - 16:00 **Parallel 17.4 The Effects of Novel Cereblon-binding Immunomodulators on Primary Effusion Lymphoma and Burkitt's Lymphoma**, [Emma Treco](#)

16:00 - 16:15 **Parallel 17.5 Targeting Vulnerability of EBV Infection for Vaccine Development**, [Mu-Sheng Zeng](#)

16:15 - 16:30 **Parallel 17.6 A Lymph Node Targeted Molecular Adjuvant and Engineered Subunit Antigen Vaccine Promotes Potent Cellular and Humoral Immunity to Epstein - Barr virus in HLA-Expressing Mice**, [Vijayendra Dasari](#)

Parallel Session 18 Virus Host Interactions IV

3:00 - 4:30pm Tuesday, 2nd July

Georgian Room

Moderators Rui Guo, Andrew McGuire

15:00 - 15:15 **Parallel 18.1 The N6-Methyladenosine (m6A) Reader Protein YTHDF2 Is a Negative Regulator of The KSHV Nuclease SOX**, [Rakesh Sarkar](#)

15:15 - 15:30 **Parallel 18.2 Modulation of Lymphotoxin α Surface Expression by Kaposi's Sarcoma-Associated Herpesvirus K3 through Glycosylation Interference**, [Soowon Kang](#)

15:30 - 15:45 **Parallel 18.3 Exploring Human Interleukin 6 (hIL6-) and Viral Interleukin 6 (vIL-6) Transcript Regulation in the face of KSHV-mediated Global RNA Decay**, [Yahaira Bermudez](#)

15:45 - 16:00 **Parallel 18.4 CRISPR Genetic Analyses of Genome-wide Lymphoblastoid B-cell NF- κ B Target Genes**, [Bidisha Mitra](#)

16:00 - 16:15 **Parallel 18.5 ORF48 is Required for Optimal Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus**, [Beatriz Veronese](#)

16:15 - 16:30 **Parallel 18.6 KSHV Hijacks SOX18 Pioneering Activity to Facilitate Latent DNA Replication**, Krista Tuohinto

4:45 - 5:00pm

Tuesday, 2nd July

Grand Ballroom B & Ballroom Foyer

Coffee & Soft Drinks will be available from 4:30 - 5:00 PM

Parallel Session 17 (continued) Vaccines II: Therapeutics, Clinical Care

4:45 - 6:00pm Tuesday, 2nd July

Grand Ballroom A

Moderators Zhen Lin, Sidney Ogolla

16:45 - 17:00 **Parallel 17.7 Towards Improving Models of EBV-Associated Diffuse Large B-cell Lymphoma to Investigate New Therapeutic Strategies**, Aisling Ross

17:00 - 17:15 **Parallel 17.8 LANA1 CR1 deletion as a candidate for a therapeutic KSHV antigen vaccine**, Li Wan

17:15 - 17:30 **Parallel 17.9 Split Dosing of Nanatinostat (Nstat) and Impact on Anti-Tumor Activity in EBV-Infected Solid Tumors**, Ayman Elguindy

17:30 - 17:45 **Parallel 17.10 Implementation of a point-of-care diagnostic technology for Kaposi's Sarcoma for Sub-Saharan Africa**, Jason Manning

17:45 - 18:00 **Parallel 17.11 EBV-FlowRNA in the Diagnosis of EBV-Related Lymphoproliferative Disease**, Claire Shannon-Lowe

Parallel Session 18 (continued) Virus Host Interactions IV

4:45 - 6:00pm Tuesday, 2nd July

Georgian Room

Moderators Jian Zhu, Matthew Weirauch

16:45 - 17:00 **Parallel 18.7 The Role of EBV BRRF1 Gene in Host Alternative Splicing Interference**, Trang Nguyen

17:00 - 17:15 **Parallel 18.8 The Cancer-Risk Variant of EBNA1 Improves Nasopharyngeal Carcinoma Risk Prediction in an EBNA1 IgA Assay**, Benjamin Warner

17:15 - 17:30 **Parallel 18.9 EBV Infection and Immune Response Dynamics in Human Tonsil Organoids**, Mahina Tabassum Mitul

17:30 - 17:45 **Parallel 18.10 The interaction of Kaposi's sarcoma-associated herpesvirus processivity factor ORF59 with the cellular paraspeckle component SFPQ is crucial for lytic replication,** Subhash Verma

17:45 - 18:00 **Parallel 18.11 Epstein-Barr Virus (EBV) Protein LMP1 Inhibits the Unfolded Protein Response (UPR) in Telomerase-immortalized Normal Oral Keratinocytes (NOKs),** Deo Singh

Gala Dinner (for all those who registered extra, name badges include Gala on the back, please wear you name badge to the event)

7:00 - 10:00pm Tuesday, 2nd July

Avenue 34 at the Hilton Boston Park Plaza

WEDNESDAY, JULY 3, 2024

Continental Breakfast

7:15 - 8:00am Wednesday, 3rd July

Grand Ballroom B & Ballroom Foyer

Plenary Session 19 Viral entry/egress/assembly

8:00 - 10:00am Wednesday, 3rd July

Grand Ballroom A

Moderators Jennifer Corcoran, Michael McInatosh

08:00 - 08:15 **Plenary 19.1 Glycoprotein K8.1 is critical for liver and bone marrow tropism of Kaposi's sarcoma-associated herpesvirus (KSHV) in the non-human primate marmoset infection model,** Alexander Hahn

08:15 - 08:30 **Plenary 19.2 Recombinant mAbs Define Sites of Vulnerability on the KSHV gH/gL Complex,** Andrew McGuire

08:30 - 08:45 **Plenary 19.3 Identifying Entry Receptors for KSHV in B cells,** Beniah Brumbaugh

08:45 - 09:00 **Plenary 19.4 Visualization of Nuclear Egress in KSHV-Reactivated Cells,** Ariana Calderón-Zavala

09:00 - 09:15 **Plenary 19.5 Novel Epstein-Barr Virus gp42 Antibodies Reveal Sites of Vulnerability for Receptor Binding and Fusion to B cells,** Wei Bu

09:15 - 09:30 **Plenary 19.6 Dissecting the Mechanisms Underlying the Formation of Herpesvirus Assembly Compartments Mediated by Liquid-liquid Phase Separation,** Hongyu Deng

09:30 - 09:45 **Plenary 19.7 Characterizing the subcellular localization of Kaposi's sarcoma-associated herpesvirus essential packaging factor ORF68**, Sara Gelles-Watnick

09:45 - 10:00 **Plenary 19.8 Genome-wide CRISPR/Cas9 Library Screening Identifies EBV Entry Host Factors in B cells**, Hongbo Wang

Coffee Break

10:00 - 10:15am Wednesday, 3rd July
Grand Ballroom B & Ballroom Foyer

Plenary Session 20 Cancer risk variants, pathogenesis

10:15am - 12:30pm Wednesday, 3rd July
Grand Ballroom A
Moderators Qian Zhong, Zhiqiang Qin

10:15 - 10:30 **Plenary 20.1 Genomic Analyses of Epstein-Barr Virus (EBV) Discover Risk Variants of EBV Associated With Post-transplant Lymphoproliferative Disorder**, Alan KS Chiang

10:30 - 10:45 **Plenary 20.2 Characterization of EBV DNA in Saliva of an Asymptomatic University Cohort**, Logan George

10:45 - 11:00 **Plenary 20.3 A Selective HDAC-PROTAC Activates a Host Switch Upstream of the EBV Latent-to-Lytic Switch ZEBRA**, Beth Rousseau

11:00 - 11:15 **Plenary 20.4 Repression of Productive Lytic Replication by KSHV LANA Correlates with Reduced Gammaherpesvirus-specific Adaptive Immunity**, Steven Murdock

11:15 - 11:30 **Parallel 20.5 WT1 Upregulation by Lytic Induction of Kaposi Sarcoma Herpesvirus**, Ayana Morales

11:30 - 11:45 **Plenary 20.6 Uncovering the EBV Genomic Landscape in Sub-Saharan Africa: Implications for Burkitt Lymphoma**, Elshafa Ahmed

11:45 - 12:00 **Plenary 20.7 Targeting latency switch for the treatment of EBV+ lymphoma**, Isabella Kong

12:00 - 12:15 **Plenary 20.8 Cloning and Analysis of an EBV Strain from an LCL Established with a Kenyan Breast Milk-Derived Virus**, Rob White

12:15 - 12:30 **Plenary 20.9 Characterization of EBV infection in tonsils of children residing in malaria holoendemic region of western Kenya**, Emmily Koech

12:30 - 12:45 **Closing Statements**

Moderators Benjamin Gewurz, Kenneth Kaye

POSTER SESSION 1 PRESENTATIONS

- P1.1 Epstein-Barr virus- and genotype- dependent transcriptional regulation at multiple sclerosis risk loci, [Marissa Granitto](#)**
- P1.3 The Oral Microbiome by HIV infection and KSHV shedding status in a rural Ugandan population, [Katherine Sabourin](#)**
- P1.5 Distinct Genomic Features of Transeurasian Strains of Epstein-Barr Virus, [Hiroshi Kitamura](#)**
- P1.6 Risk Factors for and Patterns of Oral Shedding of Kaposi's Sarcoma-Associated Herpesvirus – a Systematic Review, [Katherine Sabourin](#)**
- P1.7 EBV Genomic Landscape in Multiple EBV+ Malignancies Reveals Distinctive Geographic-Constrained Characteristics., [Rosario Distefano](#)**
- P1.8 Evaluation of triage performance of the Epstein–Barr virus C promoter methylation assay in serology positive population: validation in two mass nasopharyngeal carcinoma screening cohorts, [Sumei Cao](#)**
- P1.9 Haplotype Analysis of EBV Genomes in Nasopharyngeal Carcinoma and Prediction of High Risk EBV Lineage Using a Panel of Nine SNPs, [Alan Kwok Shing Chiang](#)**
- P1.10 The Interplay Between EBV Subtypes and Host Genetic Factors on NPC Susceptibility, [Miao Xu](#)**
- P1.11 EBV Latency Programs Modulate Sensitivity to Necroptosis in a BCL6 Dependent Manner, [Nina Beri](#)**
- P1.12 Heat Shock Factor 2 sustains the lytic cycle of both oncogenic human gamma-herpesviruses, [Silvia Gramolelli](#)**
- P1.13 XPB, the Translocase and Helicase of TFIIH, Regulates KSHV DNA Replication and Late Gene Expression, [Harriet Song](#)**
- P1.14 Re-analysis of plasma EBV bisulfite sequencing shows novel differentially methylated CpG sites in EBV(+) cancers, [Wendell Alejo](#)**
- P1.15 A GC-rich DNA cis Element in the KSHV Genome Drives the Elevated Expression of the KSHV Lytic Gene ORF75 in Kaposi's Sarcoma Lesions, [Ashwin Nair](#)**
- P1.16 HuSH EBV: An unexpected inhibitory complex of EBV in Burkitt Lymphoma, [Madilyn Ellis](#)**
- P1.18 Novel Multiplex RT-qPCR for Detection of EBV RNA in EBV Associated Gastric Cancer Tissue, [Aisha Babi](#)**

- P1.19 Advancing Primary Effusion Lymphoma Treatment: The Pivotal Role of a New Epigenetic Therapy Combining KDM4A and HDAC Inhibition, [Pei-Ching Chang](#)**
- P1.20 EBV Antigen Expression in the Tonsils of Patients with Infectious Mononucleosis, [Aoife Hennessy](#)**
- P1.21 Local CD4 T Cell Response in Pediatric Patients With EBV Infection, [Paola Andrea Chabay](#)**
- P1.22 Modulation of Inflammasomes During Latent Kaposi's Sarcoma Herpesvirus Infection, [Christina Yap](#)**
- P1.23 Proteome-wide analysis reveals a core Epstein-Barr Virus antibody signature for classic Hodgkin Lymphoma., [Yomani Sarathkumara](#)**
- P1.25 Increased HHV-8 Neutralising Response during Remission from Kaposi's Sarcoma, [Frank Neipel](#)**
- P1.26 Generating a Mouse Model Able to Recapitulate Kaposi Sarcoma Herpesvirus-Associated Malignancies., [Vicenta Trujillo](#)**
- P1.27 Estimating the Replication and Segregation Efficacy of KSHV Episomes, [Madeleine Gastonguay](#)**
- P1.28 Single cell transcriptome of EBV+ lymphomas and lymphadenopathies from people living with HIV, [Maria Montserrat Aguilar Hernandez](#)**
- P1.29 Polycomb Group Proteins Modulate Viral Transcription and Prevent Episome Clearance of KSHV, [Adam Grundhoff](#)**
- P1.30 Chemotherapeutic agents induce Epstein-Barr virus lytic reactivation in epithelial cells through caspase-dependent apoptosis and downregulation of IFIT protein expression, [Chon Phin Ong](#)**
- P1.31 NSUN1/2-mediated RNA m5C modification controls KSHV viral infection via regulating RNA stability of host restriction factors, [Zhenyu Wu](#)**
- P1.32 Dynamic Landscapes: The Role of m6A Machinery in Reshaping the Transcriptome during Viral Infection, [Kyla Gomard-Henshaw](#)**
- P1.33 Vascular Endothelial Growth Factor Receptor (VEGFR3/FLT4) Regulates the KSHV Replication Cycle, [Ameera Mungale](#)**
- P1.34 Bruton's Tyrosine Kinase Activates the NLRP3 Inflammasome to Reactivate Epstein-Barr Virus from Latency, [Travis Zeigler](#)**
- P1.35 The Histone H3K79 Methyltransferase DOT1L Restricts EBV Lytic Reactivation, [Jinjie Yan](#)**
- P1.36 Human Herpes Virus-8 Shedding Heterogeneity is Due to Varying Rates of Reactivation from Latency and Immune Containment, [Warren Phipps](#)**

- P1.37 Autophagy is Maintained at a Constant Level at Different Levels of Lytic Reactivation and at the Production of Virions of Epstein-Barr Virus, [Jia Xie](#)**
- P1.38 Histone Demethylase KDM1A restricts EBV lytic reactivation, [Yifei Liao](#)**
- P1.39 Hypoxia induces a 5-methyl-THF trap that remodels host and viral epigenome during EBV de novo infection, [Larissa Havey](#)**
- P1.40 PD-L1 Exosome Has a Potential as a Prognostic Factor in Nasopharyngeal Carcinoma, [Eiji Kobayashi](#)**
- P1.41 Dependence of EBV-positive Diffuse Large B Cell Lymphomas on ZFP91 Unveils Susceptibility to a Novel CELMoD, [Huanzhou Xu](#)**
- P1.42 Morphological Analysis of EBV-Positive Nasopharyngeal Carcinoma Cells, [Shigetaka Komura](#)**
- P1.43 Characterization of single nucleotide and structural variations in the Epstein–Barr viral genome, [Htet Thiri Khine](#)**
- P1.44 Defining the Role of Epstein-Barr Virus (EBV) in Diffuse Large B-Cell Lymphoma (DLBCL) Pathogenesis, [Quincy Rosemarie](#)**
- P1.45 Insights into the Curious Absence of EBV-driven Lymphoma in X-linked Lymphoproliferative Disease 2 (XLP2) Patients, [Yizhe Sun](#)**
- P1.46 Epstein-Barr virus Selective Whole Genome Amplification Combined with Multiplex PCR Allows For Long-read Sequencing and Accurate Whole Genome Assembly from Burkitt lymphoma, [Enrique Puig III](#)**
- P1.47 Epstein-Barr Virus Types in Childhood Cancers: Assessment in a Malawian Cohort, [Gabriela Samayoa Reyes](#)**
- P1.48 Acetyl-CoA Carboxylase Alpha elevated by LMP1 Promotes Malignant Behavior of Nasopharyngeal Carcinoma by modulating lipid metabolism, [Zhe Zhang](#)**
- P1.50 Sulfonated Cyclodextrins are Virucidal against KSHV and EBV and Mitigate KSHV Infection in Vivo., [Alma Delia Valencia-Camargo](#)**
- P1.51 The VSV-based EBV GB Vaccine Elicits a Robust Immune Response Against EBV Infection, [Guo-Long Bu](#)**
- P1.52 Saliva Kaposi Sarcoma Herpesvirus Levels as a Diagnostic Marker of Visceral Kaposi Sarcoma, [Matthew Witterholt](#)**
- P1.53 Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 for evaluating the in vivo immunogenicity and efficacy of KSHV vaccine candidates, [Wan-Shan Yang](#)**

- P1.54 Dendritic Cell-Based Vaccines (KSD-101) Against EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study, [Chunrui Li](#)**
- P1.55 A Chimeric gH/gL Nanoparticle Vaccine Elicits Robust Protective Humoral Immunity Against EBV and KSHV, [Chu Xie](#)**
- P1.56 Development of Human Single-Chain Variable Fragment (scFv) Phage Library Targeting KSHV Proteins, [Ziyi Liu](#)**
- P1.57 Title: A Case Report of Epstein-Barr Virus (EBV) Infection: Clinical Presentation and Management, [Uwesu Muki](#)**
- P1.58 A Complex Case Report of Kaposi's Sarcoma in a Patient from Tanzania: Clinical Challenges and Management Strategies, [Uwesu Muki](#)**
- P1.59 Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma with or without other KSHV-associated Diseases, [Ramya Ramaswami](#)**
- P1.60 Virus-Like Particle AP205 Based Vaccine Candidates Elicit Strong Protective Responses against Epstein-Barr Virus Infection, [Yanan Peng](#)**
- P1.61 Exploration of Lysine Targeting Covalent Inhibitors of Epstein-Barr Virus Nuclear Antigen 1: Towards Anti-EBV Therapeutics, [Elizabeth Day](#)**
- P1.62 The Impact of EBV Strains and Genes on Epithelial Cell Infection Mediated by EBV-Transformed Human B Cells, [Ming-Han Tsai](#)**
- P1.63 Investigating the Oligomeric State of KSHV ORF68, an Essential Viral Genome Packaging Factor, [Olaide Adeyemi](#)**
- P1.64 Protective Anti-gB Neutralizing Antibodies Targeting Two Vulnerable Sites for EBV-Cell Membrane Fusion, [Miao Xu](#)**
- P1.65 Infection of Human Differentiated Cardiomyocytes by an Oncogenic Virus, [Jiaojiao Fan](#)**
- P1.66 EBV infection mediated BDNF expression is associated with bladderinflammation in interstitial cystitis/bladder pain syndrome with Hunner's lesion, [Chih-Wen Peng](#)**
- P1.67 Investigating Type 1 and Type 2 Epstein-Barr Virus Persistence in Human Immune Compartments Using Humanized Mice, [Saskia Müller](#)¹**
- P1.68 EBV's BPLF1 Deubiquitinates mTOR and Dysregulates its Downstream Targets, [Rachel Mund](#)**
- P1.69 Neuropilin-1 as a host dependency factor of Kaposi Sarcoma Herpesvirus/Human Herpesvirus-8, [Anna Serquina](#)**
- P1.70 Cerebral Brain Organoid Co-Culture: A Novel Technique to Study the Temporal and Spatial Dynamics of EBV+ B-cell Invasion, [Danielle Burner](#)**

- P1.71 Exploring the Role of Interferon-alpha in Endemic Burkitt Lymphoma Pathogenesis and Rituximab Efficacy, [Ann Kinyua](#)**
- P1.72 Syncytin-1 Sequesters Viral LF2 to Enhance the Epstein-Barr Virus Lytic Phase., [Ibukun Akinyemi](#)**
- P1.73 Merkel cell polyomavirus ALTO activates NF- κ B signaling like EBV LMP1 but suppresses tumorigenesis and is silenced in Merkel cell carcinoma, [Nick Salisbury](#)**
- P1.74 Understanding the Role of Interindividual Variability in the Response to EBV Infection of Primary B Cells, [Francesco Baccianti](#)**
- P1.75 Heterogeneous Outcomes of Myeloid Cell Infection by MHV68 Implicate Interferon Signaling as a Potential Regulator, [Rachael E. Kostelecky](#)**
- P1.76 Dynamic Repertoire of MHV68-Infected B Cells and Persistent Expression of the ORF46 Viral Uracil DNA Glycosylase in Latency, [Kevin McBride](#)**
- P1.77 An Epstein-Barr Virus Protein Interaction Map Reveals NLRP3 Inflammasome Evasion via MAVS UFMylation, [Stephanie Pei Tung Yiu](#)**
- P1.78 Structural Basis of KicGAS Self-oligomerization and its Inhibition of cGAS, [Fanxiu Zhu](#)**
- P1.79 Dihydrotestosterone boosts the MICA-mediated cytotoxicity via EBV lytic reactivation, [Hyojeung Kang](#)**
- P1.80 Developing a Primate-Like Small Animal Model to Investigate Epstein-Barr virus (EBV)-Infection and Associated Diseases, [Hiroto Dochi](#)**
- P1.81 Spatial Transcriptomics of Patients with Kaposi Sarcoma Identifies Mechanisms of Immune Evasion, [Joseph Ziegelbauer](#)**
- P1.82 Systematic Examination of EBV Transcriptional Regulator Interactions with the Host Genome, [Phillip J. Dexheimer](#)**
- P1.83 Genotype-Dependent Binding of Viral Protein Zta to Autoimmune-Associated Genetic Variants, [Carmy Forney](#)**
- P1.84 Elimination of EBV-infected B-cells with a Novel Combination Regimen, Nanatinostat and Valganciclovir, Provides Potential Therapeutic Benefit in a Humanized Mouse Model of Multiple Sclerosis, [Ayman Elguindy](#)**
- P1.85 Interrogating Patient Susceptibility and Resistance to Epstein-Barr Virus Infection in the Nasopharynx using Organotypic Cultures, [Joshua Walston](#)**

POSTER SESSION 2 PRESENTATIONS

P2.1 Isolation, Purification, and Characterization of KSHV and KSHV Viral Particles in Infection Models, [Akash Mody](#)

P2.2 Impact of MHV-68's Hepatotropism on a Subsequent Liver Infection by Malaria Parasites, [Andreia Mósca](#)

P2.3 Spectrum of KSHV/HHV8 and EBV Related Lymphoproliferative disorders: Challenges in the Daily Routine., [Lorenzo Leoncini](#)

P2.4 Burden, Pattern, Associated Factors and Impact on Quality of Life of Dermatological Disorders among the Elderly in Ilala Municipality, Dar es Salaam., [Uwesu Muki](#)

P2.5 Clinical features and prognostic factors of adult systemic chronic active Epstein-Barr virus disease: A retrospective analysis using Japanese registry data, [Hiroshi Yasui](#)

P2.7 Sex differences in anti-EBV antibody responses, [Zhiwei Liu](#)

P2.8 Shedding of Kaposi Sarcoma-associated Herpesvirus (KSHV) and Epstein-Barr Virus (EBV) DNA in Oral Fluids of Rural Community-Dwelling Adults and Adolescents in Uganda, [Kyle Moore](#)

P2.9 Genome sequence analysis clarifies Epstein-Barr virus genome variations enhances clinicopathological features of nasopharyngeal cancer in non-endemic area, Japan, [Satoru Kondo](#)

P2.10 What's Old is New Again: Arginine Metabolism Supports EBV Latency in Burkitt Cells Due to Obligatory Roles in Pyrimidine Biosynthesis, [Shaowen White](#)

P2.11 Epstein-Barr Virus is Required for Continued Proliferation of Newly Derived Endemic Burkitt Lymphoma Cell Lines, [Alexandria Bartlett](#)

P2.12 Characterizing Methylation of EBV DNA in Tumors and Plasma Using a Novel Quantitative Method, [Logan George](#)

P2.13 Epstein-Barr Virus (EBV) DNA methylation patterns in liquid biopsies inform viral reactivation and disease course in lymphoproliferative disease, [Christoph Weigel](#)

P2.14 LANA cross-links to KSHV terminal repeat (TR) regulate episome maintenance and epigenetic programming, [Paul Lieberman](#)

P2.15 Modular Assembly of an Infectious Clone of EBV Akata using Synthetic Genomics Methods in Yeast, [Sydney Ghoreishi](#)

P2.16 B-cell Receptor Isotype and the Epstein-Barr Virus (EBV) LMP2A Oncogene Regulate Distinct Genes in EBV Transformed Cells, [Mariah Riel](#)

- P2.17 Comparative Functional Screens Highlight a Role for CDK9 in KSHV Late Gene Transcription, [Chad Stein](#)**
- P2.18 Promoter Binding by the KSHV Late Viral Transcriptional Activator Requires an Extended DNA Binding Domain and Cytoplasmic Assembly of the Transcription Preinitiation Complex, [Lidia Llacsahuanga-Allcca](#)**
- P2.19 Epigenetic Regulation of EBV Viral Kinase BGLF4in EBV+ CNS Lymphoproliferative Disease as a Potential Biomarker for Antiviral Susceptibility, [Haley Klimaszewski](#)**
- P2.20 EBV Lytic Reactivation Attenuates Interferon Signaling through m6A Modification of the Host Epitranscriptomes, [Dipayan Bose](#)**
- P2.21 Genome-Wide Analysis of Epstein-Barr Virus (EBV) in Lymphoma Patients from Ethiopia, [Elshafa H Ahmed](#)**
- P2.22 ISG15 Emerges as a New Pro-Viral Host Factor in EBV-Mediated B-Cell Transformation., [Nicolas Reinoso-Vizcaino](#)**
- P2.24 High-Throughput In-Silico Exploration of T-Cell Responses to Kaposi Sarcoma Herpesvirus, [Shashidhar Ravishankar](#)**
- P2.25 Persistence of T-cell dysfunction is associated with lack of treatment response in Kaposi sarcoma, [Andrea M.H. Towlerton](#)**
- P2.26 High Levels of Antibodies Target the C-Terminus of EBNA1 in Acute Infectious Mononucleosis, [Krishna kumar Ganta](#)**
- P2.27 EBV Latent Infection Activates the Keap1-NRF2 Antioxidant Defense, [Shunbin Ning](#)**
- P2.28 The Chromatin Loop Release Factor WAPL Regulates EBV Latency Status by Restricting LMP Production, [Laura Murray-Nerger](#)**
- P2.29 Characterization of the Latency-Associated Nuclear Antigen SUMO-Interacting Motif in Kaposi's Sarcoma-Associated Herpesvirus (KSHV), [Catarina Costa](#)**
- P2.30 Human Genome-wide CRISPR/Cas9 Screen Reveals STEEP1 as a Key Host Factor for LMP1 Trafficking and Signaling, [Shunji Li](#)**
- P2.31 Utilizing Single-Cell RNA Sequencing to Uncover Host Factors Involved in Preventing Successful EBV Lytic Reactivation, [Lauren Haynes](#)**
- P2.32 Epstein-Barr Virus-Induced Nodules on Viral Replication Compartments Contain RNA Processing Proteins and a Viral Long Noncoding RNA, [Richard Park](#)**

P2.33 A Deep Mutational Scanning Approach to Identify Key Residues of Viral Transcriptional Activators Necessary for Late Gene Transcription, [Nicholas R. Doak](#)

P2.34 Transcriptome Reprogramming of Epstein-Barr Virus Infected Epithelial and B Cells Reveals Distinct Host-virus Interaction Profiles, [Nian Ma](#)

P2.35 Unraveling the Role of G-Quadruplexes in Kaposi's Sarcoma-Associated Herpesvirus DNA Replication., [Subhash Verma](#)

P2.36 KSHV lytic replication is dependent on eIF3D, [Craig McCormick](#)

P2.37 Visualization of Nuclear Egress in KSHV-Reactivated Cells, [Ariana Ariana Calderón-Zavala](#)

P2.38 Identification of Synthetic Lethality in Epstein-Barr Virus Associated Gastric Cancer, [Yin Wang](#)

P2.39 Genome-wide CRISPRi Screen to Identify Host Long Non-coding RNA Dependencies of KSHV Infection, [Sarah McMahon](#)

P2.40 Characterizing the Antiviral activity of SLFNs during MHV68 infection., [Sheila Gonzalez](#)

P2.41 Epstein-Barr virus in HIV-associated conjunctival squamous cell carcinoma, [Hiroto Dochi](#)

P2.42 Molecular Studies in Patients from Argentina with EBV+ Diffuse Large B-cell Lymphoma, not Otherwise Specified (EBV+ DLBCL, NOS) and DLBCL with Viral Traces., [Paola Chabay](#)

P2.43 Epstein-Barr virus uses different B NRF1 splicing variants depending on the situation, [Shiori Endo](#)

P2.44 KSHV Infection Leads to Osteosarcoma in Xinjiang Uyghur Population, [Yan Yuan](#)

P2.45 PD-L1 Expression by Myeloid Derived Suppressor Cells in Pediatric Hodgkin Lymphoma, [Paola Chabay](#)

P2.46 Assessment of Potential Transforming Properties of KSHV gL as Revealed Through Rhesus Macaque Rhadinovirus Chimeras Expressing KSHV Envelope Glycoproteins, [Ryan Estep](#)

P2.47 Identifying cellular gene dependencies in EBV-positive Burkitt Lymphoma, [Isabella Castellano-Moen](#)

P2.48 Peritumoral SPARC expression is induced by exosomes from tumor cells and is associated with poor prognosis in the patients with Epstein-Barr virus-associated nasopharyngeal carcinoma., [Tomokazu Yoshizaki](#)

P2.50 Kaposi Sarcoma (KS) Patient-derived Xenografts from Skin Tumors Exhibit High Expression Levels of Viral Genes and Hallmark KS Genes, [Xiaofan Li](#)

P2.51 Comparison of antibody functions between people living with HIV and KSHV in the United States and Zambia, [Marina Tuyishime](#)

P2.52 Exploring DARPins to Detect MHC-I Restricted Antigen Presentation, [Sandra Schmid](#)

P2.53 Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses, [Edward Briercheck](#)

P2.54 Multivalent MVA-Vectored Vaccine Elicits EBV Neutralizing Antibodies in Rhesus Macaques that Reduce EBV Infection in Humanized Mice, [Brenda Alvarado](#)

P2.55 Establish an Immunosuppressive Regimen in Common Marmosets (*Callithrix jacchus*) for use in Viral Challenge Experiments, [Esther Rodriguez](#)

P2.56 Targeting HERV-K by ART drugs for the treatment of Primary Effusion Lymphoma, [Anuj Ahuja](#)

P2.57 Caspase-mediated AURKA cleavage at Asp132 is essential for viral and paclitaxel-induced cell apoptosis, [Xiaoting Chen](#)

P2.58 Kaposi's sarcoma-associated herpesvirus (KSHV)-associated primary effusion lymphoma (PEL) tumor formation in NOD/SCID mice is inhibited by treatment with the anti-inflammatory Lipoxin A4, [Neelam Sharma-Walia](#)

P2.60 Identification of new natural products for preventing primary infection of an oncogenic herpesvirus, [Zhiqiang Qin](#)

P2.61 Neuropilin-1 is a universal host factor mediating herpesvirus infection., [Zheng-Zhou Lu](#)

P2.63 Kaposi's sarcoma-associated herpesvirus (KSHV) gB dictates a low-pH endocytotic entry pathway as revealed by a dual-fluorescent virus system and a rhesus monkey rhadinovirus (RRV) expressing KSHV gB, [Alexander Hahn](#)

P2.64 The Role of Epstein Barr Virus (EBV) in Pathogenesis of EBV-associated T/NK Lymphoproliferative Diseases, [Zhaoqin Zhang](#)

P2.65 Exploring the Role of Epstein-Barr Virus in MS Pathogenesis Through the Lens of Atypical B Cells, [Gillian Horn](#)

P2.66 Evidence for Variant EBV-Positive B-Cell Subtypes Associated with MS, [Leena Yoon](#)

P2.68 PIAS1 Regulates Episome Maintenance to Control the Life Cycles of EBV, KSHV and HPV, [Febri Sugiokto](#)

P2.71 Mechanism of APOBEC3B Relocalization by Epstein-Barr virus BORF2, [Farren Clark](#)

P2.72 Epstein–Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes., [Lorenzo Leoncini](#)

P2.73 The DNA Repair Machineries for Double-strand DNA Breaks Circularize KSHV and HSV, [Shijun Li](#)

P2.74 Elucidating the Pathogenic Mechanisms of Angiopathy in Systemic Chronic Active Epstein-Barr Virus Disease through Induced Pluripotent Stem Cell-Derived Endothelial Cells, [Miwako Nishio](#)

P2.75 Profiling of Epstein-Barr virus glycoproteins-host interactome by chemical proteomics, [Lanyi Zhong](#)

P2.76 EBV Antigen Expression and the Spatial Immune Landscape of Tonsils from Patients with Infectious Mononucleosis, [Cira Leahy](#)

P2.77 The Presence of LMP1 in the Tumour Cells of Caucasian Patients with ENKTL is Associated with an M1-Macrophage Rich Tumour Microenvironment and Predicts Longer Overall Survival, [Cira Leahy](#)

P2.78 Host and viral gene regulation by circular RNAs in EBV-positive B cells, [Takanobu Tagawa](#)

P2.79 EBV Infection Induces RSAD2 and CMPK2 to Promote Viral Latency and Modulate Interferon Response, [Urvi Zankharia](#)

P2.80 An Oxygen-Independent Role for eIF5B in Translation Initiation during KSHV Replication and Oncogenesis, [Christian McDonald](#)

P2.81 Methylation of KSHV vCyclin by PRMT5 Contributes to Cell Cycle Progression and Cell Proliferation, [Danping Niu](#)

P2.82 Prediction of Caspase Cleavage Sites in KSHV Proteins: Validation of K5 as another KSHV Caspase Target, [David Davis](#)

P2.85 EBNA2 Activates DNA Damage Response for Immune Evasion, [Eleni Anastasiadou](#)

ePoster 1 (please view through the online program) Degradation of TRIM32 is induced by RTA for Kaposi's Sarcoma-Associated Herpesvirus lytic replication, [Yulin Zhang](#)

PROGRAM AT A GLANCE

Saturday, June 29	
17:00	Welcome & Introductions - Plenary Session 1 Coinfections - Terrace Room
19:15	Welcome Reception - Statler Room
	Grand Ballroom A Georgian Room
Sunday, June 30	
7:15	Continental Breakfast & Registration - Grand Ballroom B & Foyer
8:00	Plenary Session 2 Tumor Microenvironment
10:00	Coffee Break
10:30	Keynote Address I - Ethel Cesarman
11:00	Parallel Session 3 Epigenetics, Gene Expression & Reactivation II Parallel Session 4 Innate & Adaptive Immunity I: Viral Evasion
13:00	Lunch Break Panera Bread
14:45	Parallel Session 5 Epigenetics, Gene Expression & Reactivation II Parallel Session 6 Lytic Cycle/Viral Replication/Reactivation I
16:45	Coffee Break
17:00	Keynote Address II Elliott Kieff Memorial Lecture - Nancy Raab-Traub
17:30	In Memoriam
17:45	Poster Session 1 - Statler Room
Monday, July 1	
7:15	Continental Breakfast - Grand Ballroom B & Foyer
8:00	Plenary Session 7 Transformation/oncogenesis I
10:00	Coffee Break
10:30	Keynote Address III - Thomas Schulz
11:00	Parallel Session 8 Transformation/oncogenesis II Parallel Session 9 Virus/Host Interactions I
13:00	Lunch Break Maggiano's Little Italy & KSHV 2025 Organizing Lunch MJ O'Connor's for those who signed up
14:45	Parallel Session 10 Virus/Host Interactions II Parallel Session 11 Autoimmunity including Multiple Sclerosis
16:45	Coffee Break
17:00	Henle Lecture/Keynote Address IV - Rosemary Rochford
17:30	EBV Association Meeting
	Dinner Break On-Own
20:00	Poster Session 2 - Statler Room
Tuesday, July 2	
7:15	Continental Breakfast - Grand Ballroom B & Foyer
8:00	Plenary Session 12 Virus/Host Interactions III
10:00	Coffee Break
10:30	Keynote Address V Sir Anthony Epstein Memorial Lecture - Paul Farrell
11:00	Parallel Session 13 Noncoding RNA Parallel Session 14 Innate and adaptive immunity II: RNA degradation
12:00	Parallel Session 15 Structure Parallel Session 16 Vaccines I: Disease association
13:00	Lunch Break Empire Garden in Chinatown
15:00	Parallel Session 17 Vaccines II: Therapeutics, clinical care Parallel Session 18 Virus Host Interactions IV
16:30	Coffee Break
16:45	Parallel Session 17 (continued) Vaccines II: Parallel Session 18 (continued) Virus Host
19:00	Gala Dinner (additional ticket required) - Avenue 34 at the Hilton
Wednesday, July 3	
7:15	Continental Breakfast - Grand Ballroom B & Foyer
8:00	Plenary Session 19 Viral entry/egress/assembly
10:00	Coffee Break
10:15	Plenary Session 20 Cancer risk variants, pathogenesis
12:30	Closing Statements
12:45	Adjourn

